Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
view all Clinical Trials
Overview
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
Contact
For more information about this trial or to inquire about eligibility, email [email protected] or call 215-707-1359.